Profusa to Acquire $30M PanOmics Diagnostics Platform, Targets $26M Pancreatic Market
Profusa signed a $30 million equity‐based Letter of Intent to acquire exclusive rights to BioInsights’ PanOmics™ multi-omics diagnostics platform with 3% revenue royalty and clinical samples access. Combined with a Mayo Clinic pancreatic cancer partnership targeting a $26 million annual opportunity from 13,000 US resections, this expands Profusa’s precision diagnostics franchise.
1. Letter of Intent Details
Profusa entered a Letter of Intent to acquire PanOmics™, agreeing to issue approximately $30 million in equity securities for exclusive rights and know-how, including access to clinically annotated samples for assay validation. BioInsights will receive a 3% royalty on net revenues and nominate a board member upon closing conditions and approvals.
2. Strategic Expansion Into Diagnostics
The acquisition adds a scalable multi-omics diagnostics platform to Profusa’s existing real-time biochemistry monitoring technology, positioning the company at the intersection of biosensing and precision medicine. Profusa intends to pursue additional financing to support development and integrate PanOmics with its Lumee® sensors for multi-indication diagnostics and monitoring solutions.
3. Pancreatic Cancer Opportunity
Profusa is leveraging a collaboration with Mayo Clinic to validate pancreatic cancer assays, targeting the US market of 13,000 annual resections worth an estimated $26 million revenue. The combined platform aims to accelerate lab-developed test commercialization via an established pathway of assay design, infrastructure, and clinical sample access.